RNXT Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

RenovoRx Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerRNXT

Market Cap42.1M

Cash RunwayRunway 6-12 months

Next Catalystn/a

Public Research Snapshot

RenovoRx Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates.

Pipeline

Asset	Indication	Modality	Stage	Public Note
No public pipeline rows are loaded yet.

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
No public trial rows are loaded yet.

Scientific Context

indication | men Best gift cards Best gifts for mom Best gifts for teens Best gifts for couple
indication | men Best gift cards Best gifts for mom Best gifts for teens Best gifts for couple
literature_publication | Trans-arterial gemcitabine micro perfusion of locally advanced pancreatic cancer enabled by coil plus glue embolization of a pancreaticoduodenal branch.
literature_publication | Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy.
literature_publication | XACT-guided interventional procedures: A feasibility study.

Want the full RNXT research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.